Literature DB >> 3117403

Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group.

H Akaza1, S Isaka, K Koiso, T Kotake, T Machida, A Maru, Y Matsumura, T Niijima, K Obata, H Ohe.   

Abstract

The Japanese Urological Cancer Research Group has conducted three randomized clinical studies on intravesical chemoprophylaxis of superficial bladder cancers. This paper presents a comparative analysis of the first and second of these. The protocol used in the first study was a so-called short-term schedule in which drugs (for group A, ADM 30 mg/30 ml; group B, ADM 20 mg/40 ml; group C, MMC 20 mg/40 ml; and group D, control) were administered twice a week for 4 weeks after transurethral resection (TUR), and in the second study a long-term schedule was used, in which drugs (for group E, ADM 30 mg/30 ml; group F, ADM 20 mg/40 ml; group G, MMC 20 mg/40 ml; and group H, control) were administered twice a week for 1 week, every 2 weeks for 7 weeks, monthly for 8 months, and finally once every 3 months for 1 year. In the first study 575 patients were evaluated and followed up for 5 years. The second study started 28 months later, and 607 patients were evaluated. A generally good prophylactic effect was obtained in the second study when the patients' backgrounds were adjusted in combination with the history and number of the tumors. The second study did not reveal any promoting or inhibitory effect on the progression of the recurrent tumors. There were no significant side effects in either study. The indications and the schedule for prophylactic intravesical chemotherapy should be more carefully studied.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117403     DOI: 10.1007/bf00262495

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Mutual neoplastic promotion by instillation of mitomycin C and cauterization on rat bladder urothelium.

Authors:  K Koseki; H Akaza; T Niijima
Journal:  Cancer       Date:  1986-02-15       Impact factor: 6.860

2.  Intravesical therapy with adriamycin in patients with superficial bladder tumors.

Authors:  F Edsmyr; T Berlin; J Boman; M Duchek; P L Esposti; H Gustafsson; H Wijkström; L G Collste
Journal:  Eur Urol       Date:  1980       Impact factor: 20.096

3.  Mitomycin C bladder instillation therapy for bladder tumors.

Authors:  T Mishina; K Oda; S Murata; H Ooe; Y Mori
Journal:  J Urol       Date:  1975-08       Impact factor: 7.450

4.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

5.  Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer.

Authors:  T Niijima; K Koiso; H Akaza
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Bladder cancer induced by noncarcinogenic substances.

Authors:  H Akaza; W M Murphy; M S Soloway
Journal:  J Urol       Date:  1984-01       Impact factor: 7.450

7.  Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy.

Authors:  G M Farrow; D C Utz; C C Rife
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

8.  Adriamycin instillations as recurrence prophylaxis in superficial urinary bladder cancer.

Authors:  K Jauhiainen; O Alfthan
Journal:  Ann Chir Gynaecol       Date:  1984

9.  Role of intravesical mitomycin C in management of superficial bladder tumors.

Authors:  R B Bracken; D A Swanson; D E Johnson; D De Furia; A C von Eschenbach; S Crooke
Journal:  Urology       Date:  1980-07       Impact factor: 2.649

10.  Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.

Authors:  H Zincke; D C Utz; W F Taylor; R P Myers; F J Leary
Journal:  J Urol       Date:  1983-03       Impact factor: 7.450

  10 in total
  10 in total

Review 1.  The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials.

Authors:  Richard J Sylvester; Willem Oosterlinck; J Alfred Witjes
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096

Review 2.  Long-term versus short-term introvesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis of the published results of randomized clinical trials.

Authors:  Teng Li; Yi Xing; Shu-Cheng Liu; Xiao-Min Han; Wen-Cheng Li; Min Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-10-16

3.  Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.

Authors:  H Eto; Y Oka; K Ueno; I Nakamura; K Yoshimura; S Arakawa; S Kamidono; S Obe; T Ogawa; G Hamami
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Current recommendations for the management of bladder cancer. Drug therapy.

Authors:  J A Witjes
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

5.  Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.

Authors:  K Obata; Y Ohashi; H Akaza; S Isaka; S Kagawa; K Koiso; T Kotake; T Machida; Y Matsumura; T Niijima
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Recurrence of superficial bladder tumours after transurethral resection.

Authors:  H Fuse; T Sakai; H Kimura; T Katayama
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

7.  A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.

Authors:  Y Hirao; E Okajima; S Ozono; S Samma; K Sasaki; T Hiramatsu; K Babaya; S Watanabe; Y Maruyama
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin.

Authors:  H Akaza; K Koiso; T Kotake; Y Matsumura; S Isaka; T Machida; K Obata; Y Ohashi; H Ohe; Y Ohi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study.

Authors:  Y Ohi; H Ohmori; T Shirahama; M Kawahara; Y Matsumura; T Tsushima; Y Ohashi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin.

Authors:  Y Matsumura; H Akaza; S Isaka; S Kagawa; K Koiso; T Kotake; T Machida; T Niijima; K Obata; Y Ohashi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.